Comparison of U.S. Oncology Value Frameworks and Integration with Performance-based Pricing by Lin, Wen
Comparison of U.S. Oncology Value Frameworks and Integration 
with Performance-based Pricing 
by 
Wen Jie Lin 
 
 
A master’s paper submitted to the faculty of  
The University of North Carolina at Chapel Hill 
In partial fulfillment of the requirements  
For the degree of Masters of Healthcare Administration  
In the Department of Health Policy and Management, 
Gillings School of Global Public Health 
 
Chapel Hill 
May 3rd, 2017 
 
 
    Approved by: 
 
______ _________ 
 Stacie Dusetzina 
  _ _____________________ 
                                                                Steven Pray 
1 
 
Table of Contents 
EXECUTIVE SUMMARY ..................................................................................................... 2 
INTRODUCTION ................................................................................................................... 3 
VALUE FRAMEWORKS AND THE PATIENT JOURNEY ............................................... 5 
CURRENT U.S. ONCOLOGY VALUE FRAMEWORKS ................................................... 6 
AMERICAN SOCIETY OF CLINICAL ONCOLOGY ......................................................... 7 
NATIONAL COMPREHENSIVE CANCER NETWORK EVIDENCE BLOCKS ............ 15 
INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW .............................................. 19 
MEMORIAL SLOAN KETTERING CANCER CENTER DRUGABACUS ..................... 24 
STRENGTHS AND LIMITATIONS OF VALUE FRAMEWORK APPROACHES ......... 27 
POTENTIAL OPPORTUNITIES TO INTEGRATE VALUE FRAMEWORKS INTO 
PERFORMANCE-BASED PRICING .................................................................................. 34 


















 Rising cancer drug costs within the United States have raised questions regarding the 
accessibility and affordability of these treatments to patients. To curb costs, several organizations 
created value frameworks for oncology drugs. These frameworks calculate value by measuring 
the clinical benefit of the drug and dividing it by the cost of the drug. Currently, four U.S. value 
frameworks exist: the American Society of Clinical Oncology (ASCO) Value Framework, the 
National Comprehensive Cancer Network (NCCN) Evidence Blocks, the Institute for Clinical 
and Economic Review (ICER), and the Memorial Sloan Kettering Cancer Center (MSKCC) 
Drugabacus. These frameworks are defined by their inclusion of three perspectives: the 
physician, the patient, and the payer. Each of the frameworks weighs clinical, cost, and value 
metrics differently based on the predominant perspective(s) associated with the framework. For 
example, the ASCO and NCCN frameworks are primarily used as a shared decision making tool 
due to their emphasis of the physician and patient perspectives while the ICER and MSKCC 
Drugabacus frameworks focus on the payer perspective and include population level data and 
health system ramifications. Due to these different interpretations of value, an integrated value 
frameworks approach does not exist. However, these frameworks can still be used to change the 
price of oncology drugs by combining them with performance-based pricing. The frameworks 
can drive alignment across stakeholders to define and measure clinical outcomes for 
performance-based pricing. More importantly, the frameworks can be used to create a new 
pricing process where the framework-generated value output can raise or lower the price of 
oncology drugs. This will facilitate purchase negotiations between manufacturers and payers 
based on the value of the drug to patients. While limitations like transparency concerns and 
regulatory barriers still exist, there is an opportunity to improve the overall value of oncology 
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drugs and match them to the best care pathways by providing patients with the appropriate drug 
at the right time. 
INTRODUCTION 
 Cancer is a generic term used to describe a set of diseases that is defined by the rapid 
creation of abnormal cells that grow uncontrollably and invade other parts of the body. 
According to the World Health Organization (WHO), cancer is the leading cause of morbidity 
and mortality worldwide with approximately 14 million new cases in 2012 and 8.2 million 
cancer related deaths in 2015 (World Health Organization, 2017). Treatments for cancer 
typically consist of cancer type specific treatment regimens that can include surgery, 
radiotherapy, chemotherapy and/or various other oncology drugs. However, the cost of cancer 
treatment, specifically oral oncology drugs, is far outpacing cost of living adjustments and is 
becoming an increasing burden on cancer patients. This issue is especially pressing as the WHO 
predicts that annual cancer cases will rise to 22 million within the next two decades (National 
Cancer Institute, 2017). 
 Oncology drug prices within the United States (US) have skyrocketed over the last 15 
years with the price of most patented cancer drugs increasing 5 to 10-fold (Kantarjian et al., 
2014). In 2000, the price for one year of therapy was around $10,000 whereas in 2012, 12 of 13 
new drugs approved for cancer indications were priced at above $100,000 (Kantarjian et al., 
2014). Due to the expensive nature of these drugs, insurance companies often assign them to the 
specialty drug tier. Thus, even with insurance, the patient is responsible for 20% to 30% of the 
drug or a financial burden of $20,000 to $30,000 (Kantarjian et al., 2014). In 2013, the median 
household income in the US was $51,939 so paying for these drugs will use approximately half 
of a household’s income (DeNavas-Walt & Proctor, 2014). As a result, there is a growing 
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concern regarding the affordability and ultimately the public’s accessibility to these life-saving 
drugs. Drug companies are being pressured by regulators and patients to change the pricing 
structure of oncology drugs as immuno-oncology drugs, drugs aimed at boosting the patient’s 
immune system to fight cancer, are entering the market. These drugs are often priced at a 
premium within the US with prices running over $100,000 per year of treatment (Kantarjian et 
al., 2014). The impact of these prices on patients has been especially pronounced in recent years 
as the Affordable Care Act (ACA) and other legislation have shifted the total cost of care to 
patients through higher premiums and copays (Schnipper & Bastian, 2016).   
One potential solution is the adoption of a value-based or pay for performance model for 
cancer drug pricing. However, before any changes to the pricing structure of cancer drugs can 
happen, the value of oncology drugs must be determined. Value is a very nebulous term and 
there are currently several conceptual frameworks that try to quantify the value of cancer 
treatment options (Schnipper & Bastian, 2016). This paper will analyze four existing US value 
frameworks and identify key limitations and gaps across the frameworks. The goal behind this 
analysis is to provide a foundation to create a performance-based payment system for oncology 
drugs within the US. While performance-based contracting in other therapeutic areas and other 
parts of the world exist, there are still questions about value specific to U.S. patients and the U.S. 
health system. This gap in understanding prevents the design of meaningful metrics to measure 
the performance and appropriateness of different oncology drugs.    
While this paper will use cancer drug pricing to provide a context for the current political 
climate and push for value within the US healthcare system, it will not delve into the 
appropriateness of cancer drug prices. The focus paper of this paper is on the four US based 
value frameworks and the context in which they are used to evaluate and measure cancer drugs. 
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Each of the frameworks is designed with a different audience in mind and this paper will analyze 
the categories that comprise each of the frameworks and identify similarities and differences in 
the concept of value. With this information, one can begin to tie specific metrics and themes with 
a pay for performance reimbursement system for cancer drugs. 
VALUE FRAMEWORKS AND THE PATIENT JOURNEY 
 When discussing value in the context of healthcare, there are several considerations that 
do not exist in other industries. For example, in addition to the financial considerations of paying 
for oncology drugs, there are also physical and emotional challenges that patients face when 
confronted with a diagnosis of cancer (Schnipper & Bastian, 2016). To achieve the best outcome, 
oncologists must balance all three domains when working with the patient to determine the best 
treatment option. Rising oncology drug prices are especially concerning as research has shown 
that patients are sensitive to cost and there is lower predicted benefit when there is lower 
willingness to tolerate higher copayments (Wong et al., 2010). Balancing financial pressures 
with standard of care is a relatively new theme in US healthcare but is becoming more popular as 
the industry shifts to value-based delivery. In fact, the American College of Physicians updated 
their statement of ethical principles to acknowledge that the physician owes his or her primary 
responsibility to the patient and emphasizes the importance of the physician serving as a steward 
of society’s resources in the context of caring for one’s patient (Snyder 2012). 
 Frameworks to help define the value of drugs that are used to treat cancer have increased 
in popularity in recent years. While there are similarities across the frameworks, each of them is 
different in terms of the stakeholders, the purpose and the means of assessment (Schnipper & 
Bastian, 2016). Additionally, the idea of value is a fluid concept for frameworks as any 
assessment that characterizes value at a given point in time, for a specific clinical indication, can 
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change for the better or worse as new indications or toxicities emerge (Schnipper & Bastian, 
2016). Generally, value is defined as a drug’s clinical benefit over its cost as shown in Figure 1.  
Figure 1. Definition of Value 
 
Thus, value frameworks can be assessed based on their ability to process and integrate various 
clinical benefits and cost metrics to arrive at a drug’s value. 
CURRENT U.S. ONCOLOGY VALUE FRAMEWORKS 
 Cancer care within the US is expected to account for $158 billion by 2020 (Mariotto et 
al., 2011). However, the rising costs do not account for the patient’s ability to pay for treatments.  
In a national survey of individuals with cancer, among those with insurance, 25% reported that 
they used all or most of their savings to pay for treatment and 33% of families had difficulties 
paying for cancer-related expenses (USA Today, 2006).  The increasing inability for patients to 
pay due to the rising costs of treatment is becoming a central issue among patients, physicians 
and payers within the US. In fact, it has led to several strategies including the emergence of 
clinical pathways and value frameworks when evaluating treatment options. Within the US, there 
are several value frameworks that assist physicians and patients when discussing cancer 
treatment options. The following section examines four US oncology value frameworks with a 
focus on the history of the frameworks, the various stakeholders and how they are being used to 






AMERICAN SOCIETY OF CLINICAL ONCOLOGY 
 The American Society of Clinical Oncology (ASCO) Value Framework was created in 
response to the rising costs of cancer care and their impact on patients (Schnipper & Bastian, 
2016). ASCO deemed this issue a high priority because the top 10 drugs reimbursed by Medicare 
Part B were used for cancer treatment and many of the antineoplastic agents approved by the US 
Food and Drug Administration (FDA) only offered modest improvements in progression-free or 
overall survival when compared to prevailing, less costly standard of care (Schnipper & Bastian, 
2016).  By assessing the relative value of treatments, this framework serves as a tool to promote 
shared decision-making between physicians and patients. The primary emphasis of this 
framework is ensuring that both the physician and patient are fully informed regarding the 
clinical effects and toxicities of a regimen as well as the underlying costs of the agent and 
supportive medications. The framework calculates a net health benefit score and compares it to 
the cost of treatment to explain the tradeoffs of therapy for a given patient. Data to generate the 
score comes from prospective randomized trials in which a comparator is tested against a 
standard of care. Exceptions to this standard is when antineoplastic agents are approved based on 
promising activity seen in a single-arm trial where there is no comparator (Schnipper & Bastian, 
2016). From this process, two types of ASCO frameworks have been developed: one for 
advanced disease and the other for potentially curative disease (adjuvant therapy).  
 The driving force behind the creation of the ASCO Value Framework was the 
acknowledgement that cancer care’s contribution to overall health care costs was increasing at a 
faster rate than other areas due to the aging population, the introduction of new drugs and 
therapies, and the adoption of more expensive diagnostic tests (Schnipper et al., 2015). In some 
cases, the adoption of new diagnostic or therapeutic interventions may not be well supported by 
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medical evidence with the effect of raising costs without improving patient outcomes. 
Compounding this effect are sometimes unrealistic patient and family expectations that can 
prompt a clinician to recommend new interventions without supporting evidence of utility or 
benefit (Schnipper et al., 2015). From the patient’s perspective, growing out-of-pocket health 
care costs in this area is creating an environment of financial toxicity. Per Zafar et al. (2013), 
insured patients undergoing cancer treatment and seeking copayment assistance experience 
considerable subjective financial burden and may alter their care to defray out-of-pocket 
expenses. In many instances, patients have had to reduce spending on essentials or skip 
prescribed medications and procedures due to cost concerns. Studies have shown that patients 
desire financial information about alternative treatments in addition to information about medical 
effectiveness and treatment toxicity (Ubel, 2010). The ASCO Value Framework aims to reduce 
the knowledge gap between clinician and patient regarding the best and most cost-effective 
cancer treatment option.  
 In 2007, ASCO created the Task Force on the Cost of Cancer Care with the missions of 
educating oncologists on the importance of discussing costs associated with recommended 
treatments, enabling patients to ask questions about anticipated costs of treatment options and 
identifying the drivers of the rising costs of cancer care to move towards more equal access and 
the highest-quality care at the lowest cost (Schnipper et al., 2015). Over time, this task force 
evolved from understanding and defining the costs of cancer care to focusing on value. In 2013, 
the Task Force was renamed the Value in Cancer Care Task Force and charged with developing 
a framework for comparing the relative clinical benefit, toxicity and cost of treatment in the 
medical oncology area. At its core, the framework was meant to provide a standardized approach 
to assist physicians and patients in assessing the value of a new drug treatment in cancer care 
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when compared to the prevailing standards of care (Schnipper et al., 2015). It empowers medical 
oncologists with the information and tools to assess the relative value of cancer therapies and 
share the decision-making process by presenting information to the patient on the expected cost 
of treatment and the benefit it may provide.  
 The ASCO Value Framework was created with the guidance of three core principles 
(Schnipper et al., 2015). Foremost among them is the concept that the physician-patient 
relationship is central to defining the management options for the patient. In ASCO’s view, the 
oncologist is the patient’s best advocate and resource for guidance in assessing the value of 
treatment options. Thus, the physician must have the tools and knowledge to differentiate the 
relative value of different therapies for specific clinical scenarios. The second principle is that 
patients need access to both the clinical and the cost data about their treatment options to make 
an informed decision. This scenario is only possible when patients have a clear understanding of 
the clinical benefits and harms associated with treatment options and an appreciation of the 
financial impact of each option. The final principle states that the physician has a responsibility 
to be a good steward of health care resources. To that end, the oncologist should make informed 
decisions regarding the value of care, understanding the most accurate and up-to-date 
information on the benefits and costs to patients and society. As a result, this framework was 
created with the input of four major stakeholder constituencies: oncologists, patients, payers and 
manufacturers (Schnipper et al., 2015). In its current form, the framework illustrates the 
challenges of developing a clinically useful tool in this area. While it can be used to influence 
policymakers and payers, the primary motivation is still on the physician-patient relationship. 
 When deciding on the metrics for the ASCO Value Framework, the Task Force decided 
to focus on the concept of value. As it is traditionally defined, value is measured as outcomes 
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achieved per monetary expenditure (Feeley et al., 2010). The Institute of Medicine (IOM) has 
outlined six elements of quality health care delivery including safety, effectiveness, patient 
centeredness, timeliness, efficiency and equity (Wolfe 2001). Through the Value in Cancer Care 
Task Force, ASCO has chosen to define value in cancer by emphasizing three of those elements: 
clinical benefit (efficacy), toxicity (safety) and cost (efficiency). These criteria were selected due 
to the ease and frequency of measurement in addition to being at the center of the mission of the 
clinical oncologist. 
  As previously mentioned, there are two versions of the ASCO Value Framework – one 
for advanced cancer and another for potentially curative therapy. In both framework, points are 
awarded and subtracted in the categories of clinical benefit and toxicity. For the advanced 
disease framework, bonus points can be earned if a regimen shows statistically significant 
improvement in palliation of symptoms and/or treatment-free interval compared with the control 
treatment in the clinical trial. Clinical benefit and toxicity (and bonus points for the advanced 
cancer framework) scores are combined to generate a net health benefit (NHB) score which is 
compared to the direct cost of the treatment for a summary assessment. Detailed explanations of 
the various components of the ASCO Value Framework are described below (Schnipper et al., 
2015): 
Clinical benefit. In both frameworks, clinical benefit is assigned a categorical score 







Table 1. ASCO Value Framework – Clinical Benefit 
 
Note: Reprinted from Updating the American Society of Clinical Oncology Value Framework: 
Revisions and Reflections in Response to Comments Received, by Schnipper et al., Copyright 
2016. 
 
The benefit is measured by applying the categorical score to three weighted metrics: 
median overall survival (OS), median progression-free survival (PFS), and response rate 
(RR). OS is the length of time from the start of treatment for a disease that half the 
patients are still alive when comparing a new regimen to the standard-of-care. PFS is the 
length of time where half of the patients live with the disease but it does not get worse. 
RR is the percentage of patients whose cancer shrinks or disappears after treatment 
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(Schnipper et al., 2015). In this scale, improvements in OS represent the greatest clinical 
benefit to the patient.   
Toxicity. As shown in Table 2, toxicity examines the relative toxicity of the new agent 
against standard-of-care.  
Table 2. ASCO Value Framework – Toxicity 
 
Note: Reprinted from Updating the American Society of Clinical Oncology Value Framework: 
Revisions and Reflections in Response to Comments Received, by Schnipper et al., Copyright 
2016. 
 
Depending on the level of potential harm to the patient, the toxicity category can change 
the NHB score by 20 points.  
Bonus Points. As shown in Table 3, new treatments can gain bonus points in two ways: 








Table 3. ASCO Value Framework – Bonus Points 
 
 
Note: Reprinted from Updating the American Society of Clinical Oncology Value Framework: 
Revisions and Reflections in Response to Comments Received, by Schnipper et al., Copyright 
2016. 
 
Palliation points are awarded if there is a statistically significant improvement in cancer-
related symptoms. Treatment-free interval points are earned when the patient’s disease is 
not progressing and they are spared treatment-related toxicities.  
NHB Score. The clinical benefit and toxicity scores, as well as the bonus points in the 
advanced disease framework, are combined to yield an NHB score as shown in Table 4.  
14 
 
Table 4. ASCO Value Framework – Net Health Benefit 
 
Note: Reprinted from Updating the American Society of Clinical Oncology Value Framework: 
Revisions and Reflections in Response to Comments Received, by Schnipper et al., Copyright 
2016. 
 
The maximum score is 130 for the advanced disease framework and 100 for the curative 
framework. 
Cost. Under this component, two cost estimates are considered. The first is the drug 
acquisition cost (DAC) which is the price listed by the drug manufacturer. The second 
cost estimate is the patient cost which is highly dependent on the patient’s insurance. 
Also, included in these calculations are costs associated with supportive care drugs that 
are required to administer the treatment as shown in Table 5. 
Table 5. ASCO Value Framework – Cost 
 
Note: Reprinted from Updating the American Society of Clinical Oncology Value Framework: 
Revisions and Reflections in Response to Comments Received, by Schnipper et al., Copyright 
2016. 
 
Summary Assessment. After calculating the NHB score and the cost information, the 
results are summarized in an assessment that examines the relationship between the NHB 
and the cost necessary to achieve that level of benefit as seen in Table 6. 
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Table 6. ASCO Value Framework – Summary Assessment 
 
Note: Reprinted from Updating the American Society of Clinical Oncology Value Framework: 
Revisions and Reflections in Response to Comments Received, by Schnipper et al., Copyright 
2016. 
 
 After presenting the ASCO Value Framework in 2013, the organization asked for 
comments from interested parties to refine the methodology and utility of the tool. Based on the 
results of this process, ASCO envisions additional iterations of the framework to better serve the 
needs of the physicians and patients.  
NATIONAL COMPREHENSIVE CANCER NETWORK EVIDENCE BLOCKS   
 The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of 27 
of the world’s leading cancer centers with the aim of improving the quality and effectiveness of 
care provided to individuals with cancer (National Comprehensive Cancer Network – About, 
2017). Recently, the NCCN has incorporated evidence blocks into its guidelines for various 
clinical scenarios. This tool provides physicians and patients a graded assessment of the variables 
that go into implementing treatment regimens based on NCCN recommendations (National 
Comprehensive Cancer Network - Evidence Blocks, 2017). The domains measured in this tool 
include effectiveness, safety, quality of evidence, consistency of evidence and affordability 
(National Comprehensive Cancer Network - Evidence Blocks, 2017). Each domain is assigned a 
grade from 1 (least favorable) to 5 (most favorable). 
 Similar to the other U.S. oncology value frameworks, the NCCN Evidence Blocks 
framework is intended to educate providers and patients and be a starting point for shared 
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decision-making. Understanding the clinical and scientific rationale for treatments in addition to 
the economic impact enables individuals to make informed choices based on the patient’s needs 
and values. The NCCN Evidence Blocks are a visual representation of the NCCN Guidelines 
based on input from a multidisciplinary panel of experts on appropriate interventions for cancer 
care (National Comprehensive Cancer Network - Evidence Blocks, 2017). The panel of experts 
focus on sub-specialties and incorporate new disease-specific information into the existing 
framework. Due to the framework’s visual nature, it allows for a quick and transparent view of 
the panel’s assessment of the different domains. 
 The graphical representation of the NCCN Guidelines creates an efficient way to scan 
and compare multiple therapy options. Physicians can condense the information of different 
cancer treatments into an easy-to-understand format and work with patients to choose the best 
option. Discussing the benefits and drawbacks of each of the therapies can help patients identify 
the treatment that best matches their goals and preferences. Thus, the primary stakeholders for 
this tool include everyone involved in the treatment decision-making process from physicians to 
patients and their families.  
Unlike the ASCO framework, the NCCN Evidence Blocks framework is relatively 
subjective as it is created and scored by a panel of experts and then disseminated to clinicians. 
There are currently over 48 individual panels consisting of 1,150 clinicians and oncology 
researchers from the 27 NCCN member institutions (National Comprehensive Cancer Network - 
Guidelines, 2017). Each NCCN Panel member assigns a standardized score of 1 to 5 to the 
domains based on the clinician’s understanding of the treatment. For example, the members 
score safety and efficacy based on their knowledge of published data and clinical experience 
from treating patients. Quality and consistency of clinical data is rated based on the panel’s 
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knowledge of the data supporting the treatment. Finally, affordability is graded using the 
members’ knowledge of the overall cost of treatment. Taken together, the final score for each 
domain is based on all responding panel members, rounding to the nearest whole number. The 
compiled results are used to build a 5 x 5 table that represents the NCCN Evidence Block for the 
treatment as shown in Figure 2.  
Figure 2. NCCN Evidence Blocks  
 
Note: Reprinted from National Comprehensive Cancer Network - Evidence Blocks, Copyright 2016. 
Retrieved March 03, 2017, from https://www.nccn.org/evidenceblocks/ 
 
Each column corresponds to one of the domains of efficacy (E), safety (S), quality and quantity 
of evidence (Q), consistency of evidence (C), and affordability (A) (National Comprehensive 
Cancer Network - Evidence Blocks, 2017). The rows are shaded from bottom to top based on the 
compiled score for each measure. An in-depth look at each of the categories of the NCCN 
Evidence Blocks framework is shown below: 
Efficacy (E). This measure examines the extent to which the intervention is useful in 
prolonging life, slowing disease progression, or reducing the symptoms of a medical 
condition. The scale ranges from 5 (highly effective) which provides long-term survival 




Safety (S). This refers to the relative likelihood of side effects from an intervention. A 
score of 5 (usually no toxicity) indicates uncommon or minimal side effects with little 
interference with activities of daily life (ADL) while a score of 1 (highly toxic) refers to 
severe or life threatening toxicities and high interference with ADLs.  
Quality and quantity of evidence (Q). This is the number and types of clinical trials that 
are relevant to an intervention. Panel members may weigh the depth of the evidence (the 
number and design of the clinical trials) to assign a score. A score of 5 (high quality) 
represents multiple well-designed randomized trials and/or meta-analyses while a score 
of 1 (poor quality) is little or no evidence.  
Consistency (C). This is the degree to which the clinical trials for the intervention have 
consistent results. A 5 (highly consistent) represents multiple trials with similar outcomes 
while a score of 1 (anecdotal evidence) indicates that the evidence in humans is based on 
anecdotal evidence.  
Affordability (A). This category is the overall cost of the intervention including the drug 
cost, required supportive care, infusions, toxicity monitoring management of toxicity, and 
inpatient stays with lower cost being assigned a higher score. For this scale, a 5 is very 
inexpensive while a 1 is very expensive.  
The NCCN Evidence Blocks framework primarily serves as a shared decision-making 
tool between the physician and patient. The data is organized in a visual format to allow the easy 
interpretation of recommendations and comparisons. Unlike other frameworks, the NCCN 





INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW 
 Founded in 2006, the Institute for Clinical and Economic Review (ICER) is a non-profit 
organization that evaluates evidence on the value of medical tests, treatments and delivery 
system innovations (ICER – About, 2017). Per its website, ICER’s mission is to act as an 
independent source of analysis of evidence on effectiveness and value to better understand value 
in healthcare and improve the quality of care that patients receive (ICER – About, 2017). 
Currently, the industry lacks an unbiased, trustworthy voice that can integrate all stakeholders to 
discuss transparency and value on the individual and system level. ICER aims to fill that gap 
with a systematic approach to evaluating the relationship between prices and drugs that improve 
patients’ lives. In doing so, the organization supports a broader dialogue regarding value that 
brings together stakeholders ranging from insurance companies, drug manufacturers, physicians 
and patients. Through ICER, the linking of innovation that improves patient outcomes with 
system-level cost data will generate more value to both the patients and the system. 
    ICER accomplishes its goal through a two-tiered approach that includes the following: 
(1) collaborations with patient groups, clinical experts and life science companies to generate 
reports comparing efficacy and cost of treatment options and (2) public meetings with regional 
independent panels of clinical, scientific and health policy experts to discuss the ICER reports s 
(ICER – Myths, 2017). The focus of this paper with regards to ICER will be on the reports that 
analyze drug comparative effectiveness and the value of treatments to patients and the health 
care system. For new treatment options, ICER calculates “value-based price benchmarks” based 
on how much better they are at improving patients’ lives. Per the organization, the aim of these 
reports is to identify a “win-win-win” outcome: a price that will be recognized by insurers as 
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being aligned with value, will lead to broad and affordable coverage for patients, and will reward 
innovators for the additional value they provide to patients (ICER – Myths, 2017).  
 The ICER value framework stems from the organization’s principles of not only 
developing methods of evidence assessment but also providing mechanisms for engaging 
stakeholders and the public on best practices for using evidence as the foundation for a more 
effective and sustainable health care system (ICER - VAF Update, 2017). Thus, the purpose of 
the value framework is to form the backbone of rigorous evidence reports that will help the 
United States move towards providing sustainable access to high-value care for patients. Guiding 
these efforts are an emphasis on collaboration across all stakeholders and the understanding that 
many choices in health care are subject to trade-offs as societal resources are not unlimited. 
Through the framework, the process of thinking about value in the context of health care is 
transparent and evidence-based. 
 ICER’s value framework is different compared to the other value frameworks in that it 
focuses on the conceptual framework and the methods that drive the ICER evidence reports. The 
ICER framework is focused on the “population-level” perspective instead of being used as a 
shared decision-making tool for the physician and patient at the point of care. It seeks to analyze 
evidence in a way that supports population-level initiatives such as guidelines on appropriate 
care, pricing, insurance determinations and payment mechanisms (ICER - VAF Update, 2017). 
In addition to providing a different perspective to evaluate the strengths and weaknesses of the 
available evidence, the reports can also explore potential tension between population-level 
policies and the value to individual patients.  
 The development of the ICER value framework is an iterative process as the organization 
constantly seeks feedback from stakeholders and collaborators. In February of 2017, ICER 
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proposed a new structure of the framework that examines two general concepts: “long-term 
value for money” and “short-term affordability.” Figure 3 below shows the new conceptual 
structure as well as the different domains under short-term and long-term value. 
Figure 3. ICER Update – Proposed Conceptual Structure  
 
Note: Reprinted from Institute for Clinical and Economic Review - VAF Update. Copyright 2017. 
Retrieved March 13, 2017, from http://icer-review.org/wp-content/uploads/2016/02/ICER-VAF-Update-
Proposals-020117.pdf. 
 
The following section will examine the concepts and the supporting domains in greater depth as 
well as the outputs of the ICER value framework.  
Long-term value for money serves as the anchor for the ICER value framework and is 
comprised of 4 domains: 1) comparative clinical effectiveness, 2) incremental cost-effectiveness, 
3) other benefits and advantages, and 4) contextual considerations. In addition to these domains, 
the long-term perspective in this framework promotes several ideas regarding value. First, this 
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concept acknowledges that while most clinical data is limited in duration, overall value in terms 
of outcomes for patients and costs should include a longer time horizon. Therefore, the ICER 
framework uses the full lifetime of the patient for its incremental cost-effectiveness analyses. 
Second, the evaluation of evidence on comparative clinical effectiveness of different treatment 
options forms the basis of the cost-effectiveness analysis. Third, the framework accepts multiple 
forms of evidence for determining value. In addition to randomized controlled trials (RCTs), 
ICER uses observational studies, patient reported data and long-term registries to measure long-
term benefit. Finally, the framework acknowledges that “clinical outcomes” may not include 
items that are highly valued by patients. Thus, the framework also examines “other benefits and 
disadvantages” and “contextual considerations.” A closer look at the domains is shown below: 
Comparative clinical effectiveness. This domain examines the body of evidence for the 
effectiveness of the new treatment including RCTs and other sources such as cohort 
studies and patient-reported data. This domain will include the magnitude and the level of 
certainty of the net health benefit. Additionally, ICER will attempt to include an 
evaluation of the heterogeneity of treatment effect for key clinical outcomes to address 
variations between individuals within treatment groups.  
Incremental cost-effective analysis. ICER will compare different treatment options with 
the cost per quality-adjusted life year (QALY). The cost will be estimates of the price of 
the treatment net of discounts, rebates and other price concessions. The QALY is the 
established benchmark for determining the benefits to patients from 
lengthening/improving their quality of life. After obtaining a cost per QALY, the 
treatment is placed in a range of cost-effectiveness thresholds from $50,000 to $150,000 
per QALY to guide long-term value for money.      
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Other Benefits and Disadvantages. This section of the framework explores benefits and 
disadvantages of the treatment to the patient, caregivers, delivery system or public that is 
not evident from comparative clinical effectiveness evidence. Benefits can include public 
health benefits, increased productivity, and treatment outcomes that reduce disparities 
across patient groups. Disadvantages can include increased burden on the family or 
caregiver and inability to return to work or other negative effects on productivity. There 
are several potential methods to implement this measure but the current process invites 
independent committees to consider the factors and submit votes on the impact. 
Contextual Considerations. This domain examines ethical, legal and other issues that 
influence the relative priority of illnesses and interventions. Factors that are considered 
include the likelihood of similar treatments being introduced, societal values, and the 
severity of the illness. Similar to the “other benefits and disadvantages” domain, these 
factors are judged by an independent appraisal committee.  
Short-term affordability is a complementary consideration to the “long-term value for 
money” concept when measuring value. The ICER value framework provides an explicit 
evaluation of the short-term affordability of new treatments by analyzing the potential budget 
impact of changes in health expenditures. The examination of the potential budget impact is the 
net impact across all elements of the health system. Additionally, ICER currently uses a “short-
term” time frame of 5 years. Doing so allows for the incorporation of potential clinical benefits 
and cost offsets that may not happen immediately after the adoption of a new treatment. The 
importance of this concept cannot be underestimated as short-term budget impact is a key driver 
of policy changes and decisions on how to allocate resources to maximize the quality of care.  
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 The ICER value framework is payer focused as it incorporates population level data and 
health system impact when determining the value of new oncology drugs. This information is 
used to generate evidence reports that are used by policymakers and payers to provide 
sustainable access to high-value care for patients. 
MEMORIAL SLOAN KETTERING CANCER CENTER DRUGABACUS 
 The Memorial Sloan Kettering Cancer Center (MSKCC) DrugAbacus is a tool created by 
Dr. Peter B. Bach to calculate the theoretical price of cancer drugs based on user inputs. It was 
made available in 2015 and contains a convenience sample of 52 cancer drugs approved between 
2001 and 2015 by the FDA for the treatment of cancer (DrugAbacus – FAQ, 2017). The Abacus 
theoretical price is calculated using a formula that weighs elements such as efficacy, toxicity, 
population health burden, research and development, rarity, and novelty (DrugAbacus – FAQ, 
2017). The generated theoretical price is compared to the actual market price to illustrate price 
deficits or surpluses for a given treatment. Similar to the ICER value framework, this framework 
is best used to drive policy changes and examine the population-level drug pricing. Its use as an 
assessment tool for shared decision-making between physician and patient is limited.    
 The methodology for calculating the Abacus theoretical price is a two-step process with 
user-assigned weights to each of the eight domains of the MSKCC DrugAbacus. These prices are 
relevant for a treatment period that is required to achieve the reported benefit in FDA approval 
trials. Model-calculated prices are for the duration of the treatment used in clinical trials and then 






Figure 4. MSKCC DrugAbacus 
 
Note: Reprinted from Memorial Sloan Kettering Cancer Center DrugAbacus. Copyright 2015-2017. 
Retrieved April 20th, 2017, from http://drugpricinglab.org/tools/drug-abacus/ 
 
An in-depth breakdown of the eight domains of the DrugAbacus are outlined below: 
Efficacy. This domain is measured as the improvement in overall survival or a substitute 
endpoint attributable to the drug. This score can be adjusted based on the quality of the 
clinical trial. In cases with no evidence of overall survival, progression-free survival and 
response rate can be used.  
Toxicity. This domain is characterized by the listing of the frequency and severity of side 
effects experienced by patients receiving the drug. There are two components to this 
measurement: the effect of the drug on the probability that the patient will experience a 
severe side effect and the effect of the drug on the probability of discontinuing use of the 
drug due to severe side effects. 
Novelty. The novelty of each drug is scored by two clinical experts who are involved 
with recent, related research. The experts classify each drug into one of three groups: 1) 
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novel mechanism of action, 2) drugs with known target but novel delivery, and 3) next-
in-class. 
Research and development. The number of human subjects enrolled in the approval 
trials for the first indication is used as a proxy for overall costs to develop the drug. 
Rarity. The rarity of the drug is developed from the projected incidence of the disease in 
2015 as per the American Cancer Society Facts and Figures Report. 
Population Health Burden. This domain is calculated from the estimated number of 
years of life lost due to the disease in the U.S. population. This is defined as the average 
difference between life expectancy at death and age at death from individuals suffering 
from the disease.  
Unmet need. This domain measures the social need for a drug which is determined by 
the number of recommended treatments in the NCCN’s guidelines for a drug’s target 
indication at FDA approval. 
Prognosis. This measures the severity of the disease that each drug is designed to treat. 
Median survival in the absence of intervention is gathered from the FDA label. 
Annual spending. This is the consensus estimate for expected U.S. sales in the year 2015 
according to the EvaluatePharma database. Estimated sales assumes that the volume of 
sales of each drug is not impacted by the change in price of the drug.  
The MSKCC DrugAbacus is a physician and payer focused value framework that uses 
weighted value metrics to calculate theoretical prices for drugs. These prices are compared to the 
market value of drugs to generate conversations about overall benefit and value between 




STRENGTHS AND LIMITATIONS OF VALUE FRAMEWORK APPROACHES 
 The effectiveness of a value frameworks approach to defining the value and ultimately 
the price of oncology drugs is difficult to quantify. Not only are cancer drugs expensive, they are 
also toxic with difficult to measure benefits, have high variability between patients and lead to 
modest overall improvements in patient outcomes (Basch, 2016). At their core, value 
frameworks exist as a method of combining different treatment characteristics into composite 
metrics to allow for cross-treatment comparisons, formulary prioritization and pricing 
assessments. Due to the complexities of the clinical data, there is not a single method to defining 
value for these drugs. Each framework prioritizes different inputs to arrive at recommendations 
for the patient and/or the health system as shown in Table 7. However, the end goal for these 
frameworks is the same: to determine the appropriate use of oncology drugs through the 
alignment of provider, patient and payor perspectives. The following section examines the 
strengths and the weaknesses of the value frameworks approach and its application to oncology 
drug pricing.     
Table 7. Comparison of U.S. Value Frameworks for Oncology Drugs 
Comparison of U.S. Value Frameworks for Oncology Drugs 
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✔️ ✔️ ✔️ ✔️ 
Toxicity 
 
✔️ ✔️ ✔️ ✔️ 
Quality of Life 
 
✔️ --- ✔️ --- 
Disease Burden/ 
Incidences  
--- --- ✔️ ✔️ 
Unmet Need 
 
--- --- --- ✔️ 
Novelty 
 
--- --- --- ✔️ 
Research Costs 
 
--- --- --- ✔️ 
Cost Effectiveness 
 
--- ✔️ ✔️ --- 
Budget Impact 
 
--- --- ✔️ ✔️ 
Note: Data for Data Source and Cost Data from Schnipper & Bastian (2016), for Value Metrics from 
Maervoet et al. (2016). 
Strengths of the value frameworks approach can be grouped into three main categories: 
shared decision-making between the physician and patient, defining the concept of value, and 
greater transparency. While the frameworks utilize these strengths to varying degrees, the 
benefits of understanding the balance of clinical benefit and cost as well as generating dialogue 
between the physician and patient are invaluable in this environment of rising drug prices.  
Shared decision-making. At their core, the majority of US oncology value frameworks 
act as decision-making tools for fostering patient-clinician communication (Basch, 2016). 
Due to the rising costs of cancer care, the patient specific clinical benefit conferred by 
cancer drugs, and the increasing financial burden on patients, clinicians play a greater 
role than ever in helping patients navigate different treatment options. Value frameworks 
empower patients to better understand the realities of their situation and work with their 
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provider to determine the most appropriate course of action given their needs. Although 
more emphasis on the patient perspective is required to improve the precision of value 
estimates, these frameworks serve as a first step to understanding and addressing the 
burden of oncology drugs on patients.  
Defining value. Per Schnipper & Bastian, the idea of value is very fluid (2016). Any 
assessment that examines value at a point in time for a specific clinical indication can 
change for better or worse depending on the realization of additional benefits or the 
emergence of complications. Prior to the emergence of the values frameworks approach, 
it was difficult to quantitatively define the additional value of novel therapies. This issue 
contributed to the financial burden on patients as the additional cost of new treatments 
were not measured against projected clinical benefits. With value frameworks, both 
patients and physicians can make more informed decisions because there is greater clarity 
regarding the perceived value of new drugs relative to existing treatment options.  
Increased transparency. The final strength of the frameworks approach is characterized 
by transparency both in the value determination process and in the updates to the 
frameworks. For each framework, there is a systematic approach to incorporate clinical 
benefits and cost information to arrive at value. ASCO groups inputs into clinical benefit, 
toxicity, and cost while the NCCN Evidence Blocks uses five categories consisting of 
efficacy, safety, quality, consistency, and affordability. Using well-defined criteria, both 
frameworks enable users to arrive at conclusions regarding the appropriate use of 
oncology drugs. Additionally, transparency is also evident in how organizations seek 
feedback when updating the frameworks. Both ASCO and ICER elicited public feedback 
from various stakeholders including providers, payers and pharmaceutical companies 
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before making changes to their respective frameworks. This degree of openness and 
willingness to change ensures the frameworks’ usefulness to users even in the changing 
healthcare landscape. 
 Though there are many positives to using frameworks, there are also limitations that 
reduce the effectiveness of frameworks in the real-world setting. Limitations of this approach 
revolve around three areas: overdependence on clinical trial data, lack of consistency and 
transparency with cost data, and the absence of an integrated approach to value. As with the 
strengths, each of the frameworks addresses these limitations in different ways and some are 
better at mitigating potential downsides of the frameworks approach.  
Overdependence on clinical trial data. The majority of the frameworks determine value 
by measuring clinical benefit relative to cost (Chandra & Dhawan, 2016). As a result, 
randomized clinical trials (RCTs) are often used to gauge the health benefit of each 
outcome. However, while these trials can be the standard for clinical evidence, the design 
of the studies can present challenges in a more general setting. According to Basch, 
clinical trials often include participants who are not representative of the demographic 
distribution of the general patient population and endpoints are selected to meet 
regulatory needs rather than issues of concern to patients (2016).  
Lack of consistent and transparent cost data. Due to the complex nature of drug 
pricing, it is difficult to calculate and measure a drug’s clinical benefit compared to its 
cost. Several frameworks attempt to consider patient out-of-pocket costs when 
determining overall value but the efficacy of such an approach is limited because of the 
dynamics between the payer and patient. Often, the payer is responsible for the majority 
of the cost of treatment and that burden is not necessarily reflected in the calculations. Of 
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the frameworks, only ICER considers the total cost per patient, including cases where 
pharmaceutical treatment can decrease other medical expenses such as surgery (Chandra 
& Dhawan, 2016). Other frameworks can underestimate potential benefits that improve a 
patient’s quality of life or additional costs associated with increased hospitalizations 
resulting from drug complications or side effects. Thus, there are several gaps when 
utilizing drug cost data including the lack of a consistent approach to selecting cost 
criteria across frameworks and undefined connections between cost and clinical benefit.       
Absence of an integrated approach to value. The final limitation is the absence of an 
integrated approach towards the determination of value. Since the concept of value is 
fluid, each framework interprets value differently based on the combination of inputs and 
stakeholders involved. For example, the ASCO and NCCN frameworks are primarily 
used as a shared decision-making tool to enhance provider communication with patients 
while the ICER framework examines drugs in the context of population level metrics and 
effect on the health system. A comprehensive method does not exist for measuring value 
for all stakeholders.  Therefore, frameworks can generate inconsistent results from the 
same clinical encounter, leading to a broad range of recommendations for the patient.  
The value framework approach is an important step for understanding the interplay of 
clinical benefit and cost when considering new oncology drugs. There are clear advantages to 
using frameworks to make comparisons between different treatment options and communicating 
those results to patients. Conversely, discrepancies across data sources and limited applicability 
in the real-world setting creates issues for users when attempting to apply this approach to drug 
pricing. Thus, the appropriate use of frameworks requires one to acknowledge the strengths and 
weaknesses of the approach, while being aware of the innate differences between frameworks. 
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As shown in Table 7, differences between frameworks can be grouped into primary stakeholders, 
cost data, and value metrics.    
Primary stakeholders. There are three perspectives at play in the values frameworks 
approach: the physician, the patient, and the payor. Each framework caters to a subset of 
these end users, affecting how value is calculated. For frameworks that focus on the 
physician and patient perspective, there is an emphasis on education and personalized 
metrics to measure an individual’s response to the treatment. The ASCO and NCCN 
frameworks illustrate this approach through the patient specific checklist and the 
physician-generated Evidence Blocks profile. Other frameworks embody the payer 
perspective with a focus on population-level metrics and overall health system impact.  
The ICER framework is representative of this approach as it generates a report detailing 
the short-term and long-term value of a drug. This report includes budget considerations 
and cost effectiveness measures. Additionally, there are frameworks that straddle the 
physician and payer perspectives, such as the DrugAbacus framework which generates 
user-calculated drug prices based on population and individual level metrics. Different 
perspectives can lead to drastically different interpretations of value. Each stakeholder 
has a unique set of goals which affects the framework’s structure. Thus, before one can 
use a framework to calculate a drug’s value, one must identify the framework’s intended 
audience and goal.  
Cost data. Cost is an important criterion because increasing drug prices (for patients and 
society) are the driving force behind the formation of value frameworks. As a result, all 
of the frameworks have some variation of cost as a part of their value calculation. 
However, each framework analyzes and presents cost data differently in the context of 
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the other variables being measured. For the ASCO framework, the cost of treatment is 
presented as the patient’s out of pocket cost per month and is compared against the net 
health benefit and the toxicity of the drug. NCCN Evidence Blocks compile the cost data 
under the Affordability category and assign it a score from 1 to 5 with 5 being the most 
affordable. Then, the score is displayed along with other category scores to create a visual 
representation of the drug’s characteristics. ICER has the most comprehensive formula 
for displaying cost data through short-term and long-term effects. Each ICER report 
examines short term costs like the potential budget impact of the drug and long term costs 
including incremental cost effectiveness to arrive at a “fair” price. The MSK DrugAbacus 
is like ICER because it calculates a “fair” price for drugs given a series of user inputs. 
However, unlike ICER, the tool is used closer to the point of care and allows providers 
the flexibility to adjust metrics based on the needs of their patient. Cost is important to 
value frameworks because value is commonly defined as a drug’s clinical benefit over its 
cost. Each framework uses cost in different ways. Some compare cost with other metrics 
to derive a drug’s value; other frameworks generate a fair price given various inputs. 
Additionally, the source of cost data can vary across frameworks as some only use the 
patient’s out-of-pocket expenses while others include total costs to the healthcare system.  
Value metrics. The final difference is in the breadth of value metrics that are included in 
the various frameworks. Due to the diversity of the frameworks, only a few metrics 
remain constant when shifting from one framework to the next. These metrics include 
efficacy (clinical benefit), toxicity, and cost data. They appear in all the frameworks 
because they form the core of this concept of value. The other metrics are present 
depending on the goals of the framework and the needs of the end users. For frameworks 
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that focus mainly on the payer perspective like ICER, population level metrics like 
quality of life, disease burden, cost effectiveness and budget impact are included. Those 
that incorporate physician and payer perspectives like the MSK DrugAbacus incorporates 
novelty, unmet need, and research costs into the calculations of value. Finally, the 
frameworks that are physician and patient oriented like the ASCO and NCCN 
frameworks may have a few additional metrics like quality of life or cost effectiveness. 
The stratification of value metrics is representative of the variation across value 
frameworks.              
POTENTIAL OPPORTUNITIES TO INTEGRATE VALUE FRAMEWORKS INTO 
PERFORMANCE-BASED PRICING  
The value frameworks approach emerged in response to the rising oncology drug prices. 
According to Schnipper & Bastian (2016), the goal of these frameworks is to develop a system 
for valuing medical therapies that is defined by the benefits and costs (physical and financial 
toxicity) of the therapy on patients. However, while U.S. value frameworks have been proposed 
as a method to analyze and identify value in new cancer drugs, they are still limited in their 
ability to impact the cost of new drugs. Rising oncology drug prices contribute to increased 
financial pressure and can have a negative impact on patient behavior because studies have 
shown that patients are price sensitive (Wong, et al., 2010). Currently, most US value 
frameworks are price takers. These price taking frameworks don’t attempt to directly affect the 
price of new drugs. Instead, they take the price offered by pharmaceutical companies and 
compare it to the projected clinical benefit to arrive at a value output. Treatment decisions are 
evaluated by presenting different value outputs and identifying the most appropriate option for 
the patient. While this process may affect the price of future drugs, that is not the intended goal 
35 
 
at this time. This section will examine whether it is possible for frameworks to directly impact 
the price of new oncology drugs. Both increased interest from policymakers and the rise of 
value-based contracts point to an opportunity to integrate the U.S. frameworks approach to 
performance-based pricing (PBP).         
The idea of performance-based pricing is rooted in the idea that the price set is “fair” as 
the seller is paid based on the actual performance of its product or service (Shapiro, 2002). 
However, this arrangement is difficult to achieve because the traditional relationship between a 
buyer and seller is defined by a zero-sum game where one’s gain is the other’s loss. The 
appropriate use of performance-based pricing can transform pricing into a win-win situation for 
both buy and seller. According to Harvard professor Benson Shapiro (2002), there are three 
primary advantages to performance-based pricing. The first is the alignment of the buyer’s and 
the seller’s goals. The second advantage to performance-based pricing is that it provides 
insurance to both the seller and buyer. It creates a greater sense of fairness by protecting the 
seller from undercharging the buyer and preventing the buyer from overpaying at the individual 
and institutional level. The third and final advantage is the most important because it forces the 
buyer and seller to deal with each other’s limitations, objectives and tradeoffs. In doing so, there 
is a greater appreciation of each other’s position and increased communication between the 
buyer and seller. As a practice, performance-based pricing is growing because of its economic 
logic, its ability to foster buyer/seller communication, and its successful implementation across 
different industries.         
When examining the impact of performance-based pricing on the pharmaceutical 
industry, it is important to understand the payer’s perspective. According to Stanley et al. (2012), 
payers are looking for more ways to control costs through formulary coverage restriction, 
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prescription medication distribution programs, and tiered consumer cost-sharing. Due to the 
payer’s bargaining power, manufacturers are trying to avoid losing product differentiation and 
market share in an environment that is putting increasing pressure on the price, the 
reimbursement of, and the access to pharmaceuticals (Stanley et al., 2012). Performance-based 
pricing enables pharmaceutical companies to validate the value proposition of their medication 
and redistribute the risk between payer and manufacturers. As a result, these types of agreements 
have been in use for years with an increased prevalence in recent years as European countries 
have utilized this strategy to reduce pharmaceutical drug costs in response to budgetary pressures 
(Stanley et al., 2012).  
Although performance-based pricing has been implemented in the pharmaceutical 
industry, there are still questions about how to apply the insights from those successes to 
oncology drugs. Health care in the United States presents a unique set of challenges due to the 
third-party reimbursement structure, the information asymmetry between physicians and 
patients, and the lack of consensus when determining clinical endpoints. Carlson et al. (2010) 
conducted a ten-year review (1998-2009) of performance-based health outcomes reimbursement 
schemes for medical technology, which one can use to lend insight on oncology drug pricing. 
Their analysis defined performance-based health outcomes reimbursement schemes as 
agreements between healthcare payers and medical product manufacturers in which the price, 
level or nature of reimbursement are tied to future measures of clinical or intermediate endpoints 
ultimately related to patient quality or quality of life (Carlson et al., 2010).  
As shown in Figure 5, the authors divided the schemes into two categories: conditional 
coverage, which includes conditional treatment continuation, and performance-linked 
reimbursement which includes outcome guarantees and pattern or process of care.  
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Figure 5. Performance-based Health Outcome Reimbursement Schemes 
 
Note: Reprinted from Linking payment to health outcomes: A taxonomy and examination of performance-
based reimbursement schemes between healthcare payers and manufacturers. Carlson et al. Copyright 
2010.  
 
These three types of pricing agreements are the most applicable for oncology drug development. 
Conditional treatment continuation is where continuation of coverage is based upon meeting 
short-term treatment goals. Advantages to the payer include minimizing their long-term cost 
exposure and improving the product’s cost-effectiveness by discontinuing treatment when there 
is a lack of benefit. These advantages are even greater when the manufacturer bears some of the 
cost of treatment initiation. Outcomes guarantees consist of agreements where manufacturers 
provided rebates, refunds, or price adjustments if their product did not meet certain performance 
goals. In pattern or process of care, the reimbursement is tied to the impact on clinical decision-
making or practice patterns. The performance-linked reimbursement schemes are most utilized 
when manufacturers have sufficient confidence in their product that they are willing to accept a 


















advantage of this relationship as the payer is obtaining a more cost effective product and the 
manufacturer can offer certain outcome guarantees without conducting additional product 
research or without altering the drug’s list price. Carlson et al.’s (2010) analysis shows that there 
are successful examples of performance-based pricing in the healthcare industry that can be 
applied to oncology drug pricing schemes.  
From the analysis of existing performance-based pricing schemes, one can draw 
conclusions regarding potential drug candidates and barriers to implementing such schemes 
(Stanley et al., 2012). These conclusions illustrate the strengths and limitations of performance-
based pricing and its application to oncology drugs.    
Potential drug candidates. There are two requirements for selecting drugs for which 
performance-based pricing tools could be applied. The first is identifying pharmaceutical 
products that have simple methods of measuring treatment effects and clearly defined 
outcomes (Stanley et al., 2012). The second requirement is that there are no generic 
versions of the drug on the market or soon to be on the market (Van der Heuvel, 2016). 
This is important because a generic version of the drug is assumed to have the same 
clinical outcomes so the drug must compete on cost to determine value. Additionally, 
products with a high budget impact due to their high cost or high volume of use are also 
good candidates due to the increased attention from payers. Typically, payers are focused 
on treatments in areas with high unmet need, high cost, variable treatment duration and 
uncertain long-term effects while manufacturers are focused on competitive disease areas 
like oncology (Stanley et al., 2012). Because of this, oncology drugs are a good candidate 
for performance-based pricing schemes.  
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Barriers to implementation. While performance-based pricing seems like a great idea 
for pharmaceuticals and specifically oncology drugs, there are significant barriers to 
implementation.  
Defining outcomes. The first step of any performance based agreement is to define the 
outcome being measured. Although there is clinical literature concerning appropriate 
endpoints for different treatments, getting buy-in from all stakeholders (manufacturer, 
payer, clinician, and patient) can be difficult because of stakeholder-specific interests. For 
example, pharmaceutical companies tend to measure value as the degree of improved 
efficacy over existing products on the market while payers tend to look more towards 
longevity and quality of life (Stanley et al., 2012). Moreover, estimating causality 
between the product and clinical outcome is challenging due to various externalities (life 
style, compliance etc.) outside of the manufacturer’s and payer’s control (Van der Heuvel 
et al., 2016). 
Measuring outcomes. An effective performance-based pricing scheme relies on an 
integrated system to track the progress of therapies. If a system does not exist, then 
building the infrastructure will require an upfront cost from the manufacturer and the 
payer. In addition to startup costs, other issues such as the time interval for assessments, 
appropriate sample size and shifting patient populations all contribute to measurement 
difficulties.   
Regulatory and legal barriers. Performance-based pricing is a relatively new concept for 
pharmaceutical products. Thus, limitations exist between the current U.S. pricing 
structure and one that is adapted to facilitate performance-based pricing. Within the 
United States, government pricing programs like Medicaid Best Price, Medicare Part B, 
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and 340B are not compatible with the requirements for performance-based pricing (Van 
der Heuvel, 2016). Medicaid Best Price creates a minimum floor price as pharmaceutical 
companies must offer Medicaid programs their best price regardless of the structure of 
the arrangement. For example, if a drug company offered a 50 percent rebate to a 
commercial payer for individuals who do not respond to therapy, they may then be 
required to offer certain government programs a 50 percent rebate for all uses of the 
product, regardless of product performance. There is a similar effect with Medicare Part 
B Average Sales Price Pricing as performance-based payment arrangements can lower 
the average price of a product. Another barrier in this category are the anti-kickback 
statutes. These statutes are intended to prevent fraud and abuse by prohibiting 
arrangements where inappropriate incentives can sway providers to use one product over 
another. However, they may also discourage manufacturers and payers from working 
together to create incentives structured around a drug’s adherence and efficacy in patient 
populations (Van der Heuvel, 2016).             
 As it currently stands, there are several barriers to utilizing performance-based pricing for 
oncology drugs. The frameworks approach is well suited to address some of the implementation 
challenges of performance-based drug pricing. First, use of frameworks can help stakeholders 
agree on clinical outcomes and their measurements. This alignment of stakeholders can be 
achieved through value frameworks because most of them are physician and patient focused. 
Additionally, the organizations that create these frameworks are objective because they do not 
directly participate in the purchase agreements between manufacturers and payers. Through 
frameworks, performance-based pricing participants can discuss which clinical outcomes to 
measure and the infrastructure to measure them. Second, the frameworks approach can help 
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create a pricing system that is applicable to most cancer drugs. According to Bach (2016), this 
new pricing system consists of a new process and formula. The new process will start with a 
drug price that is based on its success in initial clinical trials. That price will be recalibrated using 
real-world efficacy data, which will be integrated into a calculation of the drug’s value. Then, a 
price formula that links price with the value of a drug will provide context for value-based 
decisions regarding its use. Frameworks can facilitate links between a drug’s price to its value to 
set up performance-based pricing schemes. To maximize the effectiveness of this approach, one 
must appreciate the differences across the frameworks. Currently, there is not a prescriptive 
method that integrates all stakeholders, cost data and value metrics. While standardization for 
value metrics and cost data can be helpful, having frameworks for different users and 
perspectives leads to flexibility when designing the pricing schemes around the concept of 
value.            
CONCLUSION 
While value frameworks can lay the foundation for performance-based pricing, it is 
important to remember that there is heterogeneity across the frameworks. Currently, there is not 
an integrated framework that incorporates all stakeholders, cost data or value metrics. The ASCO 
Value Framework, the NCCN Evidence Blocks, the ICER Framework and the MSKCC 
DrugAbacus all take their own approach to calculating a drug’s value. While some 
standardization is necessary, this lack of consensus is beneficial because it incorporates the views 
of different stakeholders (physician, patient and payer) and leads to an iterative process. Each of 
these frameworks are constantly being refined to meet the needs of the end users and provide an 
adequate measure of value. As these models evolve over time, they have the potential to not only 
affect the value of a drug but also the price of a drug. Through performance-based pricing 
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schemes, these frameworks can facilitate purchase negotiations between manufacturers and 
payers based on the value of the drug to patients. Furthermore, these frameworks can help match 
cancer drugs to the best care pathways by providing patients with the appropriate drug at the 
right time. Currently, limitations such as the lack of transparency across frameworks and 
regulatory barriers in performance based pricing still exist in the pharmaceutical industry. Yet, 
with the combination of frameworks and performance-based pricing, there is an opportunity to 
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